Polaris Genomics
2 known investors
Polaris Genomics develops the ADAPT Neuropsychiatric Biomarker Discovery Platform, combining a targeted neuropsychiatric gene panel, analytics engine, and machine learning to identify genomic biomarkers from liquid biopsy for mental health and brain conditions. It serves researchers and pharma, academic, clinical, CRO, and government partners developing biomarker-based diagnostics and therapeutics in neuropsychiatry.